Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 7:30 AM ET)
Market Chameleon (Wed, 1-Apr 7:45 AM ET)
Cognition Therapeutics CEO Issues Letter to Shareholders
Globe Newswire (Tue, 31-Mar 4:30 PM ET)
Globe Newswire (Thu, 26-Mar 7:30 AM ET)
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Globe Newswire (Mon, 23-Mar 7:30 AM ET)
Globe Newswire (Tue, 17-Mar 7:30 AM ET)
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Globe Newswire (Mon, 2-Mar 7:30 AM ET)
Globe Newswire (Thu, 5-Feb 7:30 AM ET)
Globe Newswire (Tue, 27-Jan 7:30 AM ET)
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Cognition Therapeutics trades on the NASDAQ stock market under the symbol CGTX.
As of April 14, 2026, CGTX stock price was flat at $0.98 with 816,374 million shares trading.
CGTX has a beta of 3.16, meaning it tends to be more sensitive to market movements. CGTX has a correlation of 0.08 to the broad based SPY ETF.
CGTX has a market cap of $87.16 million. This is considered a Micro Cap stock.
In the last 3 years, CGTX traded as high as $3.83 and as low as $.22.
The top ETF exchange traded funds that CGTX belongs to (by Net Assets): VTI, VXF, IBRN.
CGTX has outperformed the market in the last year with a price return of +176.4% while the SPY ETF gained +31.4%. However, in the short term, CGTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -31.8% vs +0.4% return in SPY. But in the last 2 weeks, CGTX shares have fared better than the market returning +64.0% compared to SPY +9.9%.
CGTX support price is $.89 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGTX shares will trade within this expected range on the day.
